Teva Pharmaceutical: Talk About a Good Hire!

Lundbeck plunges as Teva poaches its CEO

Teva Pharmaceutical Industries Limited - Receive News & Ratings Daily

Oppenheimer Holdings, Inc. restated a "buy" rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, May 31st. Vigodman departed after Teva shares plunged to a 12-year low amid legal challenges to the company's bestselling patented drugs and price pressures on its generics. Tightening the gaze, stock performance for the last 5 trading days is -2.27%. The company holds 1.03 billion outstanding shares and 912.42 million shares are floating in market.

Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA). It has underperformed by 58.40% the S&P500.

Among 7 analysts covering Broadridge Financial Solutions (NYSE:BR), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 48% are positive. Rite Aid had 18 analyst reports since August 6, 2015 according to SRatingsIntel. Goldman Sachs maintained it with "Buy" rating and $80 target in Monday, August 10 report. The rating was downgraded by Deutsche Bank to "Hold" on Tuesday, October 11. The stock has "Hold" rating by Keefe Bruyette & Woods on Thursday, August 3. The firm has "Market Outperform" rating given on Friday, January 8 by Avondale.

Teva, which employs more than 2,000 in Pennsylvania, recently lowered its outlook for the rest of 2017, and cut its dividend payout. Morgan Stanley upgraded the shares of BAP in report on Friday, September 11 to "Overweight" rating. RBC Capital Markets maintained Landstar System, Inc. Barclays Capital has "Equal-Weight" rating and $69 target. About 336,034 shares traded. It is down 56.90% since September 11, 2016 and is uptrending. The generic drugmaker has a strong portfolio and pipeline globally in these areas and will keep on investing in the creation of long term value. Its up 0.62, from 0.79 in 2016Q3. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at approximately $106,000. 75 funds opened positions while 211 raised stakes. (NYSE:PPG). Parametric Portfolio Associate Limited owns 597,309 shares. Aperio Gru has 0.01% invested in Rite Aid Corporation (NYSE:RAD) for 122,739 shares. Cwm Lc stated it has 652 shares. Hightower Advisors Llc holds 0% or 33,845 shares. Aqr Capital Management Limited Liability Company accumulated 74,785 shares. The company has Beta Value of 0.64 and ATR value of 0.91. Retirement Systems Of Alabama invested 0.06% in Broadridge Financial Solutions, Inc. Shikiar Asset has invested 0.05% in Ultralife Corp. (NYSE:MFA) or 252,932 shares. Ppg Inds Inc now has $27.15B valuation.

Rnc Capital Management Llc increased Pepsico Incorporated (NYSE:PEP) stake by 5,176 shares to 304,628 valued at $31.87M in 2016Q4. It also reduced Twenty First Centy Fox Inc (NASDAQ:FOXA) stake by 1.02M shares and now owns 705,000 shares. SELL rating has been given by 0 analyst (s) and 4 analyst (s) given BUY rating to the stock.

One hot stock in pre-market deals on Monday is Teva Pharmaceutical Industries Ltd, whose shares are up over 12% in Tel Aviv as the world's biggest generic drug company named Kare Schultz as its new chief. The firm has "Underperform" rating by Evercore given on Friday, June 30. Royal Bank Of Canada restated an outperform rating and set a $38.00 target price (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. Creditors will loan money at a cheaper rate to a profitable company than to an unprofitable one; consequently, profitable companies can use leverage to increase stockholders' equity even more. The firm earned "Hold" rating on Thursday, August 3 by Cantor Fitzgerald.

Latest News